Free Trial

OnKure Therapeutics (OKUR) 10K Form and Latest SEC Filings 2026

OnKure Therapeutics logo
$4.52 -0.08 (-1.74%)
Closing price 04:00 PM Eastern
Extended Trading
$4.28 -0.24 (-5.40%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest OnKure Therapeutics SEC Filings & Recent Activity

OnKure Therapeutics (NASDAQ:OKUR) has submitted 251+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 10-Q submitted on May 5, 2026.

Form 4
OnKure Therapeutics, Inc. Reports Ownership Change on Apr. 3, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
OnKure Therapeutics Files Current Report on Mar. 30, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
OnKure Therapeutics Files Quarterly Report on May. 5, 2026

The 10-Q contains OnKure Therapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

OnKure Therapeutics SEC Filing History

Browse OnKure Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/05/2026 3:05 PM
OnKure Therapeutics (1637715) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/04/2026 11:15 PM
OnKure Therapeutics (1637715) Filer
Form EFFECT
04/24/2026 3:03 PM
OnKure Therapeutics (1637715) Filer
Form S-3
Registration statement under Securities Act of 1933  
04/21/2026 3:15 PM
OnKure Therapeutics (1637715) Filer
Form ARS
04/21/2026 3:15 PM
OnKure Therapeutics (1637715) Filer
Form DEF 14A
04/21/2026 3:16 PM
OnKure Therapeutics (1637715) Filer
Form DEFA14A
04/07/2026 8:14 PM
AI Biotechnology LLC (1942670) Filed by
OnKure Therapeutics (1637715) Subject
Form SCHEDULE 13D
04/07/2026 8:15 PM
Access Industries Holdings LLC (1391297) Reporting
ACCESS INDUSTRIES MANAGEMENT, LLC (1508226) Reporting
AI Biotechnology LLC (1942670) Reporting
Blavatnik Len (1326628) Reporting
OnKure Therapeutics (1637715) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/07/2026 6:21 PM
OnKure Therapeutics (1637715) Subject
StepStone Group LP (1502287) Filed by
Form SCHEDULE 13G
04/07/2026 3:30 PM
OnKure Therapeutics (1637715) Subject
Trails Edge Capital Partners, LP (2077247) Filed by
Form SCHEDULE 13G
04/07/2026 3:13 PM
OnKure Therapeutics (1637715) Subject
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Form SCHEDULE 13G
04/03/2026 2:29 PM
OnKure Therapeutics (1637715) Issuer
Saccomano Nicholas A (1609284) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/03/2026 2:25 PM
Agresta Samuel (1748961) Reporting
OnKure Therapeutics (1637715) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/03/2026 2:26 PM
Hartley Dylan (2037442) Reporting
OnKure Therapeutics (1637715) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/03/2026 2:27 PM
Leverone Jason A. (1692747) Reporting
OnKure Therapeutics (1637715) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2026 4:25 PM
OnKure Therapeutics (1637715) Issuer
Ratcliffe Liam (1547100) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2026 4:24 PM
OnKure Therapeutics (1637715) Issuer
Ratcliffe Liam (1547100) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/01/2026 10:17 AM
ACORN BIOVENTURES, L.P. (1766853) Filed by
OnKure Therapeutics (1637715) Subject
Form SCHEDULE 13G
03/30/2026 5:01 AM
OnKure Therapeutics (1637715) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/24/2026 5:56 PM
Leverone Jason A. (1692747) Reporting
OnKure Therapeutics (1637715) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/24/2026 5:57 PM
OnKure Therapeutics (1637715) Issuer
Saccomano Nicholas A (1609284) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 7:15 PM
ADAR1 Capital Management, LLC (1940272) Filed by
OnKure Therapeutics (1637715) Subject
Form SCHEDULE 13G
01/02/2026 3:16 PM
Mathers Edward T (1328625) Reporting
OnKure Therapeutics (1637715) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2026 3:10 PM
Manke Isaac (1622769) Reporting
OnKure Therapeutics (1637715) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 7:08 PM
Leverone Jason A. (1692747) Reporting
OnKure Therapeutics (1637715) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 7:09 PM
OnKure Therapeutics (1637715) Issuer
Saccomano Nicholas A (1609284) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/28/2025 7:15 AM
OnKure Therapeutics (1637715) Subject
Prosight Management, LP (1617201) Filed by
Form SCHEDULE 13G
11/21/2025 3:09 PM
OnKure Therapeutics (1637715) Filer
Form 424B3
11/18/2025 11:15 PM
OnKure Therapeutics (1637715) Filer
Form EFFECT
11/06/2025 4:25 PM
OnKure Therapeutics (1637715) Filer
Form POS AM
11/06/2025 4:08 PM
OnKure Therapeutics (1637715) Filer
Form S-3
Registration statement under Securities Act of 1933  
11/06/2025 3:13 PM
OnKure Therapeutics (1637715) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/02/2025 3:29 PM
Mathers Edward T (1328625) Reporting
OnKure Therapeutics (1637715) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2025 6:41 PM
Leverone Jason A. (1692747) Reporting
OnKure Therapeutics (1637715) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2025 6:42 PM
OnKure Therapeutics (1637715) Issuer
Saccomano Nicholas A (1609284) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/14/2025 4:28 PM
OnKure Therapeutics (1637715) Subject
Samsara BioCapital, L.P. (1699737) Filed by
Form SCHEDULE 13G/A
08/14/2025 4:20 PM
OnKure Therapeutics (1637715) Subject
PERCEPTIVE ADVISORS LLC (1224962) Filed by
Form SCHEDULE 13G/A
08/14/2025 3:09 PM
HIGHBRIDGE CAPITAL MANAGEMENT LLC (919185) Filed by
OnKure Therapeutics (1637715) Subject
Form SCHEDULE 13G
08/12/2025 3:20 PM
OnKure Therapeutics (1637715) Filer
Form 424B3
08/12/2025 3:20 PM
OnKure Therapeutics (1637715) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/12/2025 3:20 PM
OnKure Therapeutics (1637715) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/02/2025 3:33 PM
Mathers Edward T (1328625) Reporting
OnKure Therapeutics (1637715) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2025 3:16 PM
OnKure Therapeutics (1637715) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/25/2025 5:52 PM
OnKure Therapeutics (1637715) Issuer
Saccomano Nicholas A (1609284) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/25/2025 5:49 PM
Leverone Jason A. (1692747) Reporting
OnKure Therapeutics (1637715) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/30/2025 4:05 PM
Mathers Edward T (1328625) Reporting
OnKure Therapeutics (1637715) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/30/2025 2:57 PM
ACORN BIOVENTURES, L.P. (1766853) Filed by
OnKure Therapeutics (1637715) Subject
Form SCHEDULE 13D/A
05/29/2025 3:33 PM
OnKure Therapeutics (1637715) Subject
Shay Capital LLC (1723643) Filed by
Form SCHEDULE 13G
05/28/2025 3:30 PM
OnKure Therapeutics (1637715) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/27/2025 6:44 PM
ACORN BIOVENTURES 2, L.P. (1876405) Reporting
Acorn Capital Advisors GP 2, LLC (2070458) Reporting
OnKure Therapeutics (1637715) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/19/2025 4:33 PM
Chen Bihua (1599214) Reporting
Cormorant Asset Management, LP (1583977) Reporting
Cormorant Global Healthcare Master Fund, LP (1618442) Reporting
Cormorant Private Healthcare Fund III LP (1817320) Reporting
Cormorant Private Healthcare Fund IV LP (1871297) Reporting
Cormorant Private Healthcare Fund V LP (1969296) Reporting
OnKure Therapeutics (1637715) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025 2:02 PM
Cormorant Asset Management, LP (1583977) Filed by
OnKure Therapeutics (1637715) Subject
Form SCHEDULE 13G/A
05/06/2025 6:35 AM
OnKure Therapeutics (1637715) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/06/2025 6:40 AM
OnKure Therapeutics (1637715) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/06/2025 6:45 AM
OnKure Therapeutics (1637715) Filer
Form 424B3
(Data available from 1/1/2016 forward)

OnKure Therapeutics SEC Filings - Frequently Asked Questions

OnKure Therapeutics (OKUR) has submitted 251+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

OnKure Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 10-Q submitted on May 5, 2026. This was a quarterly financial update for 2025.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:OKUR) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners